Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Response to letter regarding article, “Implementation of the fifth link of the chain of survival concept for out-of-hospital cardiac arrest”.
Tagami T, Yokota H, Hirata K, Takashige T, Satake M, Matsui J, Takinami M, Satake S, Yui T, Itabashi K, Sakata T, Tosa R, Kushimoto S, Hirama H. Tagami T, et al. Among authors: hirama h. Circulation. 2013 Apr 23;127(16):e567. doi: 10.1161/circulationaha.112.154773. Circulation. 2013. PMID: 23741746 No abstract available.
Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study.
Taoka R, Kamada M, Izumi K, Tanimoto R, Daizumoto K, Hayashida Y, Uematsu K, Arai H, Sano T, Saito R, Hirama H, Kobayashi T, Honda T, Osaki Y, Abe Y, Naito H, Tohi Y, Matsuoka Y, Kato T, Okazoe H, Ueda N, Sugimoto M. Taoka R, et al. Among authors: hirama h. Int J Clin Oncol. 2024 May;29(5):602-611. doi: 10.1007/s10147-024-02481-8. Epub 2024 Feb 28. Int J Clin Oncol. 2024. PMID: 38418804
Real-world prostate-specific antigen response and progression to castration-resistant prostate cancer among men with metastatic castration-sensitive prostate cancer treated with apalutamide: a multi-institutional study in the Chu-shikoku Japan Urological Consortium.
Tohi Y, Kato T, Kobayashi K, Daizumoto K, Fukuhara H, Ohira S, Katayama S, Shimizu R, Takamoto A, Nishimura K, Ikeda K, Nagami T, Hayashida Y, Hirama H, Naito H, Tomida R, Sasaki Y, Yamamoto S, Shimizu S, Sugimoto M; Chu-shikoku Japan Urological Consortium. Tohi Y, et al. Among authors: hirama h. Jpn J Clin Oncol. 2024 Feb 7;54(2):167-174. doi: 10.1093/jjco/hyad143. Jpn J Clin Oncol. 2024. PMID: 37840362
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)-a prospective single-arm interventional study.
Sugimoto M, Kato T, Tohi Y, Shimizu Y, Matsumoto R, Inoue T, Takezawa Y, Masui K, Sasaki H, Hirama H, Saito S, Egawa S, Kamoto T, Teramukai S, Kojima S, Kikuchi T, Kakehi Y. Sugimoto M, et al. Among authors: hirama h. BMC Urol. 2022 Sep 14;22(1):151. doi: 10.1186/s12894-022-01096-3. BMC Urol. 2022. PMID: 36104667 Free PMC article.
Adverse Pathological Findings at Radical Prostatectomy following Active Surveillance: Results from the Movember GAP3 Cohort.
Marenghi C, Qiu Z, Helleman J, Nieboer D, Rubio-Briones J, Carroll PR, Lee LS, Valdagni R, Boutros PC, Nicolai N; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Marenghi C, et al. Cancers (Basel). 2022 Jul 22;14(15):3558. doi: 10.3390/cancers14153558. Cancers (Basel). 2022. PMID: 35892817 Free PMC article.
Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative.
Remmers S, Helleman J, Nieboer D, Trock B, Hyndman ME, Moore CM, Gnanapragasam V, Shiong Lee L, Elhage O, Klotz L, Carroll P, Pickles T, Bjartell A, Robert G, Frydenberg M, Sugimoto M, Ehdaie B, Morgan TM, Rubio-Briones J, Semjonow A, Bangma CH, Roobol MJ; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Remmers S, et al. Eur Urol Open Sci. 2022 Jun 14;41:126-133. doi: 10.1016/j.euros.2022.05.012. eCollection 2022 Jul. Eur Urol Open Sci. 2022. PMID: 35813247 Free PMC article.
56 results